comparemela.com
Home
Live Updates
Fosun Pharma 2021 Annual Results Announcement: Accelerating
Fosun Pharma 2021 Annual Results Announcement: Accelerating
Fosun Pharma 2021 Annual Results Announcement: Accelerating the Globalization Comprehensively
The Proportion of Revenue from Innovative Products Continues to Increase Highlights: Revenue for the year ended December 31, 2021 was RMB39,005 million,...
Related Keywords
Taiwan ,
South Sudan ,
Shanghai ,
China ,
United States ,
India ,
Hong Kong ,
Sisram ,
Haryana ,
Macau ,
Chinese ,
Han Li Kang Rituximab ,
Yi Bao ,
Wanbang Biopharm ,
Yao Pharma ,
Wu Yifang ,
Fosun Pharma ,
Axicabtagene Ciloleucel ,
Guilin Pharma ,
Xin Avatrombopag ,
Han Li Kang ,
Sinopharm Co Ltd ,
Shanghai Fosun Pharmaceutical Group Co Ltd ,
Vaccines Division ,
Innovation For Good Health ,
Pfizer ,
Innovative Medicines Division ,
National Medical Products Administration ,
Medicines Manufacturing Supply Division ,
Rating Expert Committee ,
Innovative Products Continues ,
Mainland China ,
Han Qu You ,
Shanghai Fosun Pharmaceutical ,
Stock Code ,
Social Responsibility ,
Rituximab Injection ,
Trastuzumab Injection ,
Avatrombopag Maleate Tablets ,
Gland Pharma ,
Enoxaparin Sodium Injection ,
Axicabtagene Ciloleucel Injection ,
Fosun Kite ,
New Drug Application ,
Bei Tai ,
Chinese Mainland ,
Sisram Medical ,
Fosun Diagnostics ,
Fosun Pharmaceutical Industrial ,
Medicines Patent Pool ,
Reporting Period ,
Established Medicines Manufacturing ,
Supply Division ,
Suzhou Abcarta ,
Rating Expert ,